CTMXCytomX Therapeutics, Inc.

Nasdaq cytomx.com


$ 1.21 $ 0.02 (1.69 %)    

Friday, 09-Aug-2024 15:59:47 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 1.2
$ 1.20 x 2,100
$ 1.21 x 1,600
-- - --
$ 1.04 - $ 5.85
1,303,067
na
101.86M
$ 1.05
$ 9.19
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-11-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-27-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-05-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 02-24-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-27-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 02-27-2019 12-31-2018 10-K
24 11-06-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-07-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 03-02-2017 12-31-2016 10-K
32 11-03-2016 09-30-2016 10-Q
33 08-03-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 03-07-2016 12-31-2015 10-K
36 11-23-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cytomx-therapeutics-files-250m-mixed-securities-shelf

- SEC Filing

 cytomx-therapeutics-q2-2024-gaap-eps-008-beats-010-estimate-sales-25115m-beat-19995m-estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $...

 hc-wainwright--co-reiterates-neutral-on-cytomx-therapeutics

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.

 piper-sandler-upgrades-cytomx-therapeutics-to-overweight-raises-price-target-to-35

Piper Sandler analyst Joseph Catanzaro upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweight and raises the ...

 analysts-varied-perspectives-on-cytomxs-cx-904-cancer-study-safety-profile-but-caution-in-pancreatic-cancer

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated pa...

 bmo-capital-maintains-market-perform-on-cytomx-therapeutics-raises-price-target-to-359

BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and raises the price targ...

 hc-wainwright--co-reiterates-neutral-on-cytomx-therapeutics

HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.

 wedbush-upgrades-cytomx-therapeutics-to-outperform-raises-price-target-to-8

Wedbush analyst Robert Driscoll upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Outperform and raises the price t...

 cytomx-therapeutics-q1-2024-gaap-eps-017-beats-006-estimate-sales-41463m-beat-21434m-estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $...

Core News & Articles

- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION